Unknown

Dataset Information

0

Gamma secretase inhibitors enhance vincristine-induced apoptosis in T-ALL in a NOTCH-independent manner.


ABSTRACT: Activating mutations in the NOTCH1 gene are found in over 50 % of T-ALL cases. Since Notch signaling contributes to the leukemia cell survival and growth, targeting Notch signaling using ?-secretase inhibitors (GSI) has been proposed as a molecularly targeted therapy for the treatment of T-ALL. However, not all T-ALL with NOTCH1 activating mutations respond to GSI treatment. We examined whether GSI could enhance the cytotoxic effect of anti-leukemic agents in the GSI-resistant T-ALL cells although GSI does not have anti-tumor effect as a single agent. GSI significantly increased cell death induced by Vincristine (VCR) but not other anti-leukemic drugs (Methotrexate, Asparaginase, and Cytarabine). The GSI effect in enhancing VCR efficacy was not the result of inhibition of Notch signaling. GSI augmented VCR-induced mitotic arrest, followed by apoptosis. GSI accelerated VCR-triggered loss of mitochondrial membrane potential and caspase-mediated apoptosis. Our finding suggests that GSI has other functions besides inhibiting Notch signaling in T-ALL and incorporating GSI into the conventional regimen containing VCR may offer therapeutic advantage by potentiating VCR treatment in leukemia patients.

SUBMITTER: Yoon SO 

PROVIDER: S-EPMC4198427 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Gamma secretase inhibitors enhance vincristine-induced apoptosis in T-ALL in a NOTCH-independent manner.

Yoon Sun-Ok SO   Zapata Mariana C MC   Singh Akannsha A   Jo Wol Soon WS   Spencer Nakia N   Choi Yong Sung YS  

Apoptosis : an international journal on programmed cell death 20141101 11


Activating mutations in the NOTCH1 gene are found in over 50 % of T-ALL cases. Since Notch signaling contributes to the leukemia cell survival and growth, targeting Notch signaling using γ-secretase inhibitors (GSI) has been proposed as a molecularly targeted therapy for the treatment of T-ALL. However, not all T-ALL with NOTCH1 activating mutations respond to GSI treatment. We examined whether GSI could enhance the cytotoxic effect of anti-leukemic agents in the GSI-resistant T-ALL cells althou  ...[more]

Similar Datasets

| S-EPMC3726525 | biostudies-literature
| S-EPMC2713593 | biostudies-literature
| S-EPMC8323768 | biostudies-literature
| S-EPMC8314044 | biostudies-literature
| S-EPMC9180633 | biostudies-literature
| S-EPMC2118656 | biostudies-literature
| S-EPMC6295228 | biostudies-literature
| S-EPMC8317589 | biostudies-literature
| S-EPMC5601728 | biostudies-literature
| S-EPMC2932884 | biostudies-literature